BRPI0520579A2 - composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6 - Google Patents

composto, processo para a preparação de um composto, método para o tratamento de uma desordem do sistema nervoso central relacionada a ou afetada pelo receptor 5-ht6, composição farmacêutica, uso do composto e método para testar antagonistas e antagonistas com seletividade para o receptor 5-ht6

Info

Publication number
BRPI0520579A2
BRPI0520579A2 BRPI0520579-4A BRPI0520579A BRPI0520579A2 BR PI0520579 A2 BRPI0520579 A2 BR PI0520579A2 BR PI0520579 A BRPI0520579 A BR PI0520579A BR PI0520579 A2 BRPI0520579 A2 BR PI0520579A2
Authority
BR
Brazil
Prior art keywords
compound
receptor
antagonists
affected
preparation
Prior art date
Application number
BRPI0520579-4A
Other languages
English (en)
Inventor
Venkata Satya Niro Ramakrishna
Vikas Shreekrishna Shirsath
Rama Sastri Kambhampati
Santosh Vishwakarma
Srinivasulu Kota
Venkateswarlu Jasti
Nagaraj Vishwottam Kandikere
Original Assignee
Suven Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suven Life Sciences Ltd filed Critical Suven Life Sciences Ltd
Publication of BRPI0520579A2 publication Critical patent/BRPI0520579A2/pt
Publication of BRPI0520579B1 publication Critical patent/BRPI0520579B1/pt
Publication of BRPI0520579B8 publication Critical patent/BRPI0520579B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Insulated Gate Type Field-Effect Transistor (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

COMPOSTO, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO, MéTODO PARA O TRATAMENTO DE UMA DESORDEM DO SISTEMA NERVOSO CENTRAL RELACIONADA A OU AFETADA PELO RECEPTOR 5-HT~ 6~, COMPOSIçãO FARMACêUTICA, USO DO COMPOSTO E MéTODO PARA TESTAR ANTAGONISTAS E ANTAGONISTAS COM ELETIVIDADE PARA O RECEPTOR 5-HT~ 6~. A presente invenção proporciona derivados de aminoaril sulfonamida dE fórmula (I), úteis no tratamento de uma desordem do SNC relacionada a ou afetada pelo receptor 5-HT~ 6~, o perfil farmacológico los referidos compostos incluem alta afinidade de ligação com o receptor 5-HT~ 6~ aliada a uma boa seletividade em relação ao referido receptor. A presente invenção inclui também os estereoisómeros, os sais, os métodos de preparação e um medicanento contendo os referidos derivados de aminoaril sulfonamida.
BRPI0520579A 2005-08-12 2005-10-26 composto, processo para a preparação de um composto e composição farmacêutica BRPI0520579B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1127/CHE/2005 2005-08-12
IN1127CH2005 2005-08-12
PCT/IN2005/000345 WO2007020652A1 (en) 2005-08-12 2005-10-26 Aminoaryl sulphonamide derivatives as functional 5-ht6 ligands.

Publications (3)

Publication Number Publication Date
BRPI0520579A2 true BRPI0520579A2 (pt) 2009-11-10
BRPI0520579B1 BRPI0520579B1 (pt) 2019-08-06
BRPI0520579B8 BRPI0520579B8 (pt) 2021-05-25

Family

ID=36130030

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0520579A BRPI0520579B8 (pt) 2005-08-12 2005-10-26 composto, processo para a preparação de um composto e composição farmacêutica

Country Status (22)

Country Link
US (1) US7998981B2 (pt)
EP (1) EP1919896B1 (pt)
JP (1) JP5091138B2 (pt)
KR (1) KR101016972B1 (pt)
CN (1) CN101258144B (pt)
AT (1) ATE452885T1 (pt)
AU (1) AU2005335620B2 (pt)
BR (1) BRPI0520579B8 (pt)
CA (1) CA2618636C (pt)
CY (1) CY1110276T1 (pt)
DE (1) DE602005018554D1 (pt)
DK (1) DK1919896T3 (pt)
EA (1) EA013875B1 (pt)
ES (1) ES2337167T3 (pt)
MX (1) MX2008002018A (pt)
NO (1) NO340511B1 (pt)
NZ (1) NZ566495A (pt)
PL (1) PL1919896T3 (pt)
PT (1) PT1919896E (pt)
SI (1) SI1919896T1 (pt)
WO (1) WO2007020652A1 (pt)
ZA (1) ZA200801276B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006077A (es) 2007-01-08 2009-06-17 Suven Life Sciences Ltd Compuestos de 5-(heterociclil)alquil-n-(arilsulfonil)indol y su uso como ligandos de la 5-hidroxitriptamina6.
EA016594B1 (ru) 2007-05-03 2012-06-29 Сувен Лайф Сайенсиз Лимитед Производные 1-(аминоалкоксиарилсульфонил)индола в качестве 5-нтлигандов
US7964627B2 (en) * 2007-10-26 2011-06-21 Suven Life Sciences Limited Amino arylsulfonamide compounds and their use as 5-HT6 ligands
US8318725B2 (en) 2008-09-17 2012-11-27 Suven Life Sciences Limited Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands
JP5628937B2 (ja) * 2010-01-05 2014-11-19 スベン ライフ サイエンシズ リミティド ５−ｈｔ６受容体リガンドとしてのスルホン化合物
CN102153884B (zh) * 2011-02-16 2013-06-19 连云港清泰化工有限公司 一种墨水型染料及其制备方法与用途
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals
EP3166924B1 (en) 2014-07-08 2019-02-20 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT69705A (en) * 1991-11-25 1995-09-28 Pfizer Indole derivatives
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
EP0994862B1 (en) * 1997-07-11 2005-06-01 SmithKline Beecham plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
GB9801392D0 (en) 1998-01-22 1998-03-18 Smithkline Beecham Plc Novel compounds
GB9803411D0 (en) 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
ATE327232T1 (de) * 2000-12-22 2006-06-15 Wyeth Corp Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden
CN100439370C (zh) 2001-02-08 2008-12-03 记忆药物公司 作为磷酸二酯酶4抑制剂的三氟甲基嘌呤
BR0211561A (pt) * 2001-08-03 2004-11-30 Upjohn Co Compostos e composições de 5-arilsulfonil indóis tendo afinidade para receptor 5-ht6 e seus usos
WO2003065046A2 (en) 2002-02-01 2003-08-07 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
AU2003244452A1 (en) 2002-02-05 2003-09-02 Glaxo Group Limited Method of promoting neuronal growth
JP4467307B2 (ja) * 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ５−ｈｔ受容体アンタゴニストとしてのピリジルスルホン誘導体
CA2485725A1 (en) * 2002-06-05 2003-12-18 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
RU2324693C2 (ru) 2002-10-18 2008-05-20 Ф.Хоффманн-Ля Рош Аг 4-пиперазинилбензолсульфонилиндолы, характеризующиеся сродством к рецептору 5-нт6
MXPA05005700A (es) 2002-11-28 2005-08-16 Suven Life Sciences Ltd N-arilsulfonil-3-aminoalcoxiindoles.
JP4559230B2 (ja) 2002-11-28 2010-10-06 スベン ライフ サイエンシズ リミティド セロトニン受容体に対する親和性を有する新規ｎ−アリールスルホニル−３−置換されたインドール、その調製方法、それを含有する医薬組成物
AU2003292508A1 (en) 2002-11-28 2004-06-18 Suven Life Sciences Limited N-arylalkyl-3-aminoalkoxyindoles and their use as 5-ht ligands
EA009367B1 (ru) 2002-12-18 2007-12-28 Сувен Лайф Сайенсиз Лимитед ПРОИЗВОДНЫЕ 5-ТИА-5-ДИОКСО-4b-АЗАИНДЕНО[2,1-a]ИНДЕНА, ОБЛАДАЮЩИЕ АФФИННОСТЬЮ К РЕЦЕПТОРУ СЕРОТОНИНА
ATE551997T1 (de) * 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes

Also Published As

Publication number Publication date
KR101016972B1 (ko) 2011-02-25
CA2618636C (en) 2011-01-18
EP1919896A1 (en) 2008-05-14
WO2007020652A1 (en) 2007-02-22
HK1116796A1 (en) 2009-01-02
US20100168168A1 (en) 2010-07-01
CA2618636A1 (en) 2007-02-22
MX2008002018A (es) 2008-03-27
US7998981B2 (en) 2011-08-16
ATE452885T1 (de) 2010-01-15
EP1919896B1 (en) 2009-12-23
AU2005335620A1 (en) 2007-02-22
BRPI0520579B8 (pt) 2021-05-25
EA013875B1 (ru) 2010-08-30
PT1919896E (pt) 2010-02-26
SI1919896T1 (sl) 2010-04-30
NO20080705L (no) 2008-05-06
KR20080039984A (ko) 2008-05-07
CN101258144A (zh) 2008-09-03
AU2005335620B2 (en) 2009-12-10
DE602005018554D1 (de) 2010-02-04
JP5091138B2 (ja) 2012-12-05
JP2009504633A (ja) 2009-02-05
ZA200801276B (en) 2009-02-25
ES2337167T3 (es) 2010-04-21
CY1110276T1 (el) 2015-01-14
NZ566495A (en) 2010-06-25
PL1919896T3 (pl) 2010-05-31
NO340511B1 (no) 2017-05-02
DK1919896T3 (da) 2010-04-19
CN101258144B (zh) 2012-05-30
EA200800573A1 (ru) 2008-08-29
BRPI0520579B1 (pt) 2019-08-06

Similar Documents

Publication Publication Date Title
BR0208253A (pt) Compostos, composições farmacêuticas, método de preparação de composições farmacêuticas, processo para preparação de compostos, e, uso de um composto
BR0212044A (pt) Compostos, composições farmacêuticas, método de preparação das mesmas, e, uso de um composto
BRPI0517423A (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BRPI0518459A2 (pt) composto ou um sal farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, uso de um composto, e, processo para preparar o composto ou um sal farmaceuticamente aceitÁvel do mesmo
DOP2009000133A (es) Derivados de indol como agonistas de los receptores s1p1
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI1006602A2 (pt) composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
CR9822A (es) Derivados de benzotiazol ciclobutil amina y su uso como ligandos de los receptores 3 de histamina
CY1113734T1 (el) Χημικες ενωσεις
BR0306150A (pt) Composto, uso de um composto, e, composição farmacêutica
BR0312758A (pt) Derivados de 1-heterociclilalquil-3-sulfonilazaindol ou -azaindazol como ligantes da 5-hidroxitriptamina-6
BRPI0814382A2 (pt) Composto, uso do composto, e, composição farmacêutica
CY1110276T1 (el) Αμινοαρυλο σουλφοναμιδικα παραγωγα ως λειτουργικοι συνδετες 5-ητ6
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
NO20074977L (no) Fuserte tiazolderivater med affinitet for histamin H3 receptoren
ECSP088948A (es) 4-metil-1h-pirrol-2-carboxamidas 1,3-disustituidas y su uso para la producción de medicamentos
BRPI0413584A (pt) composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de doenças e para tratamento de um distúrbio no sistema nervoso central
BRPI0412809A (pt) compostos de sulfonildihidrobenzimidazolona como ligantes a 5-hidróxitriptamina-6
BRPI0612189A2 (pt) composto, composiÇço farmacÊutica, mÉtodo para ligar receptores opiàides
BRPI0809873A2 (pt) "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento"

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO EM SUA FORMA AUTENTICADA; OU SEGUNDO O PARECER DA PROCURADORIA NO 074/93, DEVE CONSTAR UMA DECLARACAO DE VERACIDADE, A QUAL DEVE SER ASSINADA POR UMA PESSOA DEVIDAMENTE AUTORIZADA A REPRESENTAR O INTERESSADO, DEVENDO A MESMA CONSTAR NO INSTRUMENTO DE PROCURACAO, OU NO SEU SUBSTABELECIMENTO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/08/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2641 DE 17-08-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.